Among the Lp(a) research highlights, presented at the American Heart Association Scientific Sessions 2025 (7-10 November, New Orleans), were a further analysis of data from the Phase 2 OCEAN(a)-DOSE study and new insights into the role of Lp(a) in myocardial inflammation, opportunities to address barriers to Lp(a) clinical trial recruitment, projections on the impact of […]
A further analysis of data from the Phase 2 OCEAN(a)-DOSE trial has shown that olpasiran reduces Lp(a) in patients with elevated levels, irrespective of apo(a) isoform size. Small apo(a) isoforms have fewer Kringle IV-2 (KIV-2) repeats and are typically associated with higher Lp(a) concentrations compared with large apo(a) isoforms. Over 80% of people carry two […]
Changes in Lp(a), OxPL-apoB, hs-CRP, and IL-6 after acute myocardial infarction (MI) support a pathophysiologic role for Lp(a)-associated OxPLs in myocardial inflammation and highlight the potential for Lp(a) targeted therapies in the early post-MI period.1
Taking steps to improve recruitment of typically underrepresented populations in cardiovascular clinical trials can pay off, as shown by the design of the Lp(a)FRONTIERS EXPANSION trial.
Modelled projections from observational data suggest greater lowering of Lp(a) concentration may result in larger absolute reductions in recurrent coronary heart disease (CHD) risk than less Lp(a) lowering among adults with established atherosclerotic cardiovascular disease (ASCVD).1
Results of a pilot study investigating a potential connection between socioeconomic deprivation, methylation levels within the Lp(a) gene, and circulating plasma Lp(a) levels may have provided fresh insights into why plasma Lp(a) levels are up to threefold higher in African American (AA) individuals than other ethnic groups, with the associated increased risk of cardiovascular (CV) […]
